Targeting EMT in Cancer with Repurposed Metabolic Inhibitors

Ramesh V, Brabletz T, Ceppi P (2020)

Publication Type: Journal article, Review article

Publication year: 2020

Journal

Trends in Cancer Elsevier (Cell Press)

DOI: 10.1016/j.trecan.2020.06.005

Abstract

Epithelial-to-mesenchymal transition (EMT) determines the most lethal features of cancer, metastasis formation and chemoresistance, and therefore represents an attractive target in oncology. However, direct targeting of EMT effector molecules is, in most cases, pharmacologically challenging. Since emerging research has highlighted the distinct metabolic circuits involved in EMT, we propose the use of metabolism-specific inhibitors, FDA approved or under clinical trials, as a drug repurposing approach to target EMT in cancer. Metabolism-inhibiting drugs could be coupled with standard chemo- or immunotherapy to combat EMT-driven resistant and aggressive cancers.

Authors with CRIS profile

Thomas Brabletz Lehrstuhl für Experimentelle Medizin mit dem Schwerpunkt Molekulare Pathogeneseforschung Paolo Ceppi Interdisziplinäres Zentrum für Klinische Forschung IZKF Nachwuchsgruppe 1 Prof. Dr. Ceppi

How to cite

APA:

Ramesh, V., Brabletz, T., & Ceppi, P. (2020). Targeting EMT in Cancer with Repurposed Metabolic Inhibitors. Trends in Cancer. https://doi.org/10.1016/j.trecan.2020.06.005

MLA:

Ramesh, Vignesh, Thomas Brabletz, and Paolo Ceppi. "Targeting EMT in Cancer with Repurposed Metabolic Inhibitors." Trends in Cancer (2020).

BibTeX: Download